Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15090413 | 1.00 | ABL1 (0.70) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL23565661 | 0.92 | ABL1 (0.61) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL27158214 | 0.90 | ABL1 (0.59) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL23607152 | 0.88 | ABL1 (0.56) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL27159504 | 0.87 | ABL1 (0.56) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL14967819 | 0.87 | ABL1 (0.56) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL14967823 | 0.87 | ABL1 (0.56) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL25301651 | 0.86 | ABL1 (0.54) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL15090401 | 0.86 | ABL1 (0.54) | ABL1RIN1POLBP2RY6P2RY14 | |
| SCHEMBL25263770 | 0.86 | ABL1 (0.54) | ABL1RIN1POLBP2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-111808135-A | Functionally modified oligonucleotides and subunits thereof | 萨勒普塔医疗公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-10415036-B2 | Morpholino oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2019-09-17 | — | — | US | disclosed |
| US-20190211049-A1 | ANTISENSE NUCLEIC ACIDS | NIPPON SHINYAKU CO., LTD. (JP) | 2019-07-11 | — | — | US | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20160076033-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2016-03-17 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| CN-104039739-A | Functionally modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS INC | 2014-09-10 | — | — | CN | disclosed |
| US-20130197220-A1 | Morpholino Nucleic Acid Derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197220-A1 | Morpholino Nucleic Acid Derivatives | MORF4L1, METTL16, METTL3 | ABL1 1577/4885RIN1 3755/4885POLB 450/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885POLB 159/4885 |
| US-20190211049-A1 | ANTISENSE NUCLEIC ACIDS | UTRN, RBM17, UPF1 | ABL1 4457/4885RIN1 3492/4885POLB 228/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885POLB 159/4885 |
| US-10415036-B2 | Morpholino oligonucleotide manufacturing method | RNGTT, RNMT, NSUN2 | ABL1 3019/4885RIN1 4695/4885POLB 181/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885POLB 159/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885POLB 159/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885POLB 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.